MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$41,120K
EPS
-$0.19
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Collaboration revenue - related party
0 0 --
Research and development
31,164 40,156 50,200 44,713
General and administrative
13,737 14,281 14,991 16,333
Impairment of long-lived assets
0 2,382 -10,728
Total operating expenses
44,901 56,819 65,191 71,774
Loss from operations
-44,901 -56,819 -65,191 -71,774
Interest and other income, net
3,926 6,187 5,516 6,705
Interest expense
344 268 150 100
Other income (expenses), net
-81 -43 92 -1,124
Total other income (expense), net
3,501 5,876 5,458 5,481
Net loss
-41,400 -50,943 -59,733 -66,293
Net unrealized gain (loss) on available-for-sale investments
280 -88 132 937
Net comprehensive loss
-41,120 -51,031 -59,601 -65,356
Net loss per share, basic (in dollars per share)
-0.19 -0.23 -0.28 -0.32
Net loss per share, diluted (in dollars per share)
-0.19 -0.23 -0.28 -0.32
Weighted-average number of shares used in computing net loss per share, basic (in shares)
222,038,680 218,929,548 215,358,619 209,188,551
Weighted-average number of shares used in computing net loss per share, diluted (in shares)
222,038,680 218,929,548 215,358,619 209,188,551
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net comprehensiveloss-$41,120K Net unrealized gain(loss) on...$280K Interest and otherincome, net$3,926K Net loss-$41,400K Total other income(expense), net$3,501K Other income(expenses), net-$81K Interest expense$344K Loss from operations-$44,901K Total operatingexpenses$44,901K General andadministrative$13,737K Research and development$31,164K

Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. (ALLO)